Medication info
Tradium Duo Tablets 2.5/850 mg

Tradium Duo Tablets 2.5/850 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Kookje Pharmaceutical Co., Ltd.
Appearance
Bright orange, biconvex, oval, film-coated tablets
Packaging
30 tablets/box [(6 tablets/PTP x 5 units)]
Approval status
Active

MFDS item code 201802632 · Approved 2018.06.26 · Insurance code 643705530

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Inadequate glycemic control with metformin monotherapy: The initial dose of this medication is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from linagliptin and metformin combination therapy: Patients switching from linagliptin and metformin combination therapy to this medication should start with their current doses of linagliptin and metformin. 4. Inadequate glycemic control with metformin and sulfonylurea combination therapy: The initial dose should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. 5. Inadequate glycemic control with insulin and metformin combination therapy: The initial dose should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with renal impairment This medication may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
Kookje Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used for patients with type 2 diabetes who are suitable for combination therapy with linagliptin and metformin, assisting in enhancing blood sugar control alongside dietary and exercise therapies.

How to take

Adult dose

The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Inadequate glycemic control with metformin monotherapy: The initial dose of this medication is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from linagliptin and metformin combination therapy: Patients switching from linagliptin and metformin combination therapy to this medication should start with their current doses of linagliptin and metformin. 4. Inadequate glycemic control with metformin and sulfonylurea combination therapy: The initial dose should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. 5. Inadequate glycemic control with insulin and metformin combination therapy: The initial dose should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with renal impairment This medication may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication helps to control blood sugar. However, one of the active ingredients, metformin hydrochloride, can cause serious side effects such as lactic acidosis, so caution is needed. Lactic acidosis is rare but can be life-threatening if treatment is delayed, so medical attention should be sought immediately if symptoms appear. Additionally, certain patients should not take this medication. For example, individuals with an allergy to this medication, type 1 diabetes, severe renal impairment, liver dysfunction, or acute alcohol intoxication should avoid it. Pregnant or breastfeeding women are also advised against using this medication. This medication carries a risk of hypoglycemia; therefore, extra caution should be taken for low blood sugar symptoms if used with insulin or sulfonylureas. Patients with impaired renal function should have regular kidney function tests, and if renal function drops below a certain standard, this medication should be discontinued. The use of this medication should be temporarily suspended during surgery or radiological examinations, and can be resumed only after kidney function returns to normal post-surgery. Rare side effects such as acute pancreatitis or bullous pemphigoid may occur while taking this medication; therefore, if abdominal pain or skin blisters occur, immediate consultation with a doctor is required. Long-term use may cause vitamin B12 deficiency, so if anemia or neurological symptoms arise, vitamin B12 levels should be checked and supplementation may be necessary. This medication may interact with other drugs, so patients should inform healthcare providers about any medications they are taking. Pregnant women or those planning to become pregnant are recommended to opt for insulin therapy instead, and breastfeeding women should also avoid using this medication. Safety has not been established in children under 10 years or adolescents aged 10 to 17, so it is not recommended for this group. Elderly patients are at higher risk of renal function decline, so periodic kidney function testing and dosage adjustments are necessary. In cases of overdose, gastrointestinal disturbances or lactic acidosis may occur, requiring immediate medical treatment which may involve hemodialysis. This medication should be stored out of reach of children and protected from moisture.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • vitamin B12 decrease and deficiency
  • hypoglycemia
  • taste disturbance
  • cough
  • decreased appetite
Show 143 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • mouth ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • bullous pemphigoid-like condition
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • small bowel-colitis
  • bowel obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebrovascular accident
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • metastasis to the liver
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • renal transplant failure
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • benign prostatic hyperplasia
  • pruritus
  • confusional state
  • nocturia
  • dermatitis
  • hypertension
  • angina
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • rectal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • increased blood creatinine
  • facial edema
  • hyperthermia
  • back pain
  • rotator cuff syndrome
  • dizziness
  • diabetic neuropathy
  • headache
  • subdural effusion
  • palpitations
  • dry eye
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • fatty liver disease
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • chest discomfort
  • asthenia
  • pain
  • epistaxis
  • oropharyngeal pain
  • voice disorder
  • nasal bleeding
  • hyperhidrosis
  • hair loss
  • insomnia
  • osteoarthritis
  • limb pain
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. Additionally, it is important to store the drug at room temperature between 1 to 30 degrees Celsius to maintain its effectiveness and prevent deterioration.

Appearance and packaging

Appearance

Bright orange, biconvex, oval, film-coated tablets

Package unit

30 tablets/box [(6 tablets/PTP x 5 units)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.